Last reviewed · How we verify
HEV 239
At a glance
| Generic name | HEV 239 |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Injection Site Pain
- Headache
- Injection Site Induration
- Fatigue
- Myalgia
- Nausea
- Malaise
- Nasopharyngitis
- Injection Site Haemorrhage
- Pyrexia
- Haemoglobin Decreased
- Arthralgia
Key clinical trials
- Safety and Immunogenicity of Hecolin® in Healthy Pregnant Women (PHASE2)
- Effectiveness Trial to Evaluate Protection of Pregnant Women by Hepatitis E Vaccine in Bangladesh. (PHASE4)
- Safety Study of Hepatitis E Vaccine (HEV239) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HEV 239 CI brief — competitive landscape report
- HEV 239 updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI